Lymphoblastic T-cell lymphoma in mice is unaffected by Celecoxib as single agent or in combination with cyclophosphamide

References

• Dannenberg A J, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003; 4: 431–436
   PubMed Web of Science ®Google Scholar
• Paydas S, Ergin M, Erdogan S, Seydaoglu G. Cyclooxygenase-2 expression in non-Hodgkin's lymphomas. Leuk Lymphoma 2007; 48: 389–395
   PubMed Web of Science ®Google Scholar
• Kardosh A, Wang W, Uddin J, et al. Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo. Cancer Biol Ther 2005; 4: 571–582
   PubMed Web of Science ®Google Scholar
• Schonthal A H. Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br J Cancer 2007; 97: 1465–1468
   PubMed Web of Science ®Google Scholar
• Wun T, McKnight H, Tuscano J M. Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma. Leuk Res 2004; 28: 179–190
   PubMed Web of Science ®Google Scholar
• Johnson A J, Smith L L, Zhu J, et al. A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism. Blood 2005; 105: 2504–2509
   PubMed Web of Science ®Google Scholar
• Buckstein R, Kerbel R S, Shaked Y, et al. High-Dose celecoxib and metronomic “low-dose” cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res 2006; 12: 5190–5198
   PubMed Web of Science ®Google Scholar
• Eriksson B, Johansson A S, Roos G, Levan G, Holmberg D. Establishment and characterization of a mouse strain (TLL) that spontaneously develops T-cell lymphomas/leukemia. Exp Hematol 1999; 27: 682–688
   PubMed Web of Science ®Google Scholar
• Noren-Nystrom U, Eriksson M, Eriksson B, Roos G, Bergh A, Holmberg D. Antitumor activity of the angiogenesis inhibitor TNP-470 on murine lymphoma/leukemia cells in vivo and in vitro. Exp Hematol 2003; 31: 143–149
   PubMed Web of Science ®Google Scholar
• Rocca B, Spain L M, Pure E, Langenbach R, Patrono C, FitzGerald G A. Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J Clin Invest 1999; 103: 1469–1477
   PubMed Web of Science ®Google Scholar
• Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001; 15: 2742–2744
   PubMed Web of Science ®Google Scholar
• Schiffmann S, Maier T J, Wobst I, et al. The anti-proliferative potency of celecoxib is not a class effect of coxibs. Biochem Pharmacol 2008; 76: 179–187
   PubMed Web of Science ®Google Scholar
• Liu W, Chen Y, Wang W, et al. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth. Am J Clin Oncol 2003; 26: S103–S109
   PubMed Web of Science ®Google Scholar
• Blanquicett C, Saif M W, Buchsbaum D J, et al. Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clin Cancer Res 2005; 11: 8773–8781
   PubMed Web of Science ®Google Scholar
• Shaik M S, Chatterjee A, Jackson T, Singh M. Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. Int J Cancer 2006; 118: 396–404
   PubMed Web of Science ®Google Scholar
• Ponthan F, Wickstrom M, Gleissman H, et al. Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res 2007; 13: 1036–1044
   PubMed Web of Science ®Google Scholar
• Johansson A S, Eriksson M, Noren-Nystrom U, Larefalk A, Eriksson B, Holmberg D. Germ line insertions of moloney murine leukemia virus in the TLL mouse causes site-specific differences in lymphoma/leukemia frequency and tumor immunophenotype. Anticancer Res 2006; 26: 2873–2878
   PubMed Web of Science ®Google Scholar
• Zheng X, Cui X X, Avila G E, et al. Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice. Clin Cancer Res 2007; 13: 5480–5487
   PubMed Web of Science ®Google Scholar
• Dovedi S J, Kirby J A, Davies B R, Leung H, Kelly J D. Celecoxib has potent antitumour\effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma. Eur Urol 2008; 54: 621–630
   PubMed Web of Science ®Google Scholar
• Niederberger E, Tegeder I, Vetter G, et al. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB. FASEB J 2001; 15: 1622–1624
   PubMed Web of Science ®Google Scholar
• Arber N, Eagle C J, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355: 885–895
   PubMed Web of Science ®Google Scholar
• Smith M R, Manola J, Kaufman D S, Oh W K, Bubley G J, Kantoff P W. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 2006; 24: 2723–2728
   PubMed Web of Science ®Google Scholar
• Solomon S D, Wittes J, Finn P V, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008; 117: 2104–2113
   PubMed Web of Science ®Google Scholar
• Di Cello F, Hillion J, Kowalski J, et al. Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts. Mol Cancer Ther 2008; 7: 2090–2095
   PubMed Web of Science ®Google Scholar
• Tong C T, Howard S A, Shah H R, et al. Effects of celecoxib in human retinoblastoma cell lines and in a transgenic murine model of retinoblastoma. Br J Ophthalmol 2005; 89: 1217–1220
   PubMed Web of Science ®Google Scholar
• Farooqui M, Li Y, Rogers T, Poonawala T, Griffin R J, Song C W, Gupta K. COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer 2007; 97: 1523–1531
   PubMed Web of Science ®Google Scholar
• Johnsen J I, Lindskog M, Ponthan F, et al. Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res 2004; 64: 7210–7215
   PubMed Web of Science ®Google Scholar
• Cui W, Yu C H, Hu K Q. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin Cancer Res 2005; 11: 8213–8221
   PubMed Web of Science ®Google Scholar
• Klenke F M, Gebhard M M, Ewerbeck V, Abdollahi A, Huber P E, Sckell A. The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice. BMC Cancer 2006; 6: 9
   PubMedGoogle Scholar
• Simon L S, Weaver A L, Graham D Y, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282: 1921–1928
   PubMed Web of Science ®Google Scholar